Silence Therapeutics Archives

Silence Therapeutics and Mallinckrodt Announce Collaboration to Develop and Commercialize RNAi Therapeutics for Complement-mediated Diseases

LONDON and STAINES-UPON-THAMES, United Kingdom, Jul. 18 (Korea Bizwire) — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Silence Therapeutics plc (LON: SLN), a leader in the discovery, development and delivery of novel RNA2 interference (RNAi) therapeutics for the treatment of serious diseases, today announced a collaboration that will allow the companies to develop [...]

SLN124 Granted Orphan Drug Designation by EMA for the Treatment of β-Thalassemia

London, Jan. 15 (Korea Bizwire) – Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that its lead medicine candidate SLN124 has been granted Orphan Drug Designation by the Committee for Orphan Medicinal Products (COMP), the [...]